Radiotherapy Clinical Trial
Official title:
Fractional Exhaled NO, Extended NO Analysis and NO/CO Diffusing Capacity in Patients Receiving Thoracic Radiation Therapy: a Single Centre Study
NCT number | NCT03431740 |
Other study ID # | 2017-01374 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | February 15, 2018 |
Est. completion date | April 1, 2021 |
Verified date | April 2021 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators aim to investigate the impact of thoracic radiation therapy on diffusion capacity of the lung (primary endpoint: diffusion capacity for nitric oxide, DLNO) and on exhaled nitric oxide.
Status | Terminated |
Enrollment | 3 |
Est. completion date | April 1, 2021 |
Est. primary completion date | April 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - planned but not already commenced radiation therapy (RT) of the chest, with or without pre-RT surgery. - signed informed consent of the participant Exclusion Criteria: - thoracic RT in the past - treatment with immune checkpoint inhibitors - unstable condition affecting participation in the measurements |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital of Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in diffusing capacity for nitric oxide (DLNO) | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | ||
Secondary | Diffusing capacity for carbon monoxide (DLCO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Transfer Coefficient for nitric oxide (DLNO/VA) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Transfer Coefficient for carbon monoxide (DLCO/VA) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Ratio of DLNO and DLCO | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Alveolar-capillary membrane-diffusing capacity for carbon monoxide (DMCO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Pulmonary capillary blood volume (Vc) | This variable is a calculated variable. The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Alveolar Volume (VA) | This variable is a calculated variable. The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Fractional concentration of exhaled nitric oxide at a flow rate of 50mL/s (FENO50) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Concentration of nitric oxide in the gas phase of the alveolar or acinar region (CANO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Tissue concentration of nitric oxide of the airway wall (CawNO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Airway compartment diffusing capacity of nitric oxide from the of of the airway wall to the gas stream (DawNO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Total flux of nitric oxide in the conducting airway compartment (JawNO) | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Forced expiratory volume in 1 second | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Forced vital capacity | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT | |
Secondary | Forced expiratory flow between 25% and 75% of forced vital capacity | The course over time will be described. | Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
Completed |
NCT03280719 -
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02428049 -
Radiation Pneumonitis After SBRT for NSCLC
|
||
Recruiting |
NCT04923620 -
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
|
||
Active, not recruiting |
NCT05371795 -
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
|
N/A | |
Recruiting |
NCT03210428 -
Quantitative MR Imaging in Locally Advanced Cervical Cancer
|